Cor Vasa 2025, 67(6):751-757

Neuregulin-1 and Cardiovascular Diseases

Lutfu Askin^a, Yahya Urkmez^b, Hakan Ozerol^c

^a Department of Cardiology, Gaziantep Islamic Science and Technology University, Gaziantep, Turkey

^b Department of Internal Medicine, Gaziantep City Hospital, Gaziantep, Turkey

^c Department of Emergency Medicine, Gaziantep City Hospital, Gaziantep, Turkey

Cardiac tissue expresses neuregulin-1 (NRG-1), a growth factor. NRG-1 may treat heart failure (HF), myocardial infarction, cardiomyopathy, and arrhythmias. NRG-1 improves angiogenesis, cardiomyocyte development, and cardiac fibrosis in HF. These effects increase left ventricular function and minimise cardiac events (CE). NRG-1 reduces myocardial infarct size and promotes tissue regeneration. Angiogenesis and reduced inflammation and fibrosis in the infarcted region by NRG-1 minimise the incidence of unfavourable CE. NRG-1 improves left ventricular function and cardiac fibrosis in cardiomyopathy. NRG-1 modulates ion channels and reduces cardiac inflammation and fibrosis to lower arrhythmia risk. NRG-1 modulates ion channels and reduces cardiac inflammation and fibrosis in arrhythmias. NRG-1-based therapeutics for cardiovascular dis- eases (CVDs) are promising, but further research is required to maximise their usage. However, NRG-1 as a therapeutic target for CVDs is an exciting area of research that may lead to new and better treatments for these common and serious conditions.

Keywords: Cardiovascular diseases, Left ventricular function, Neuregulin-1

Received: February 21, 2025; Revised: February 21, 2025; Accepted: March 24, 2025; Prepublished online: June 2, 2012; Published: December 15, 2025  Show citation